KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process. PMID 41352456 · Radiother Oncol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial. PMID 41319450 · Eur J Cancer · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Gain of visceral adipose tissue rather than low skeletal muscle mass is associated with overall survival in patients with colorectal liver metastases; results from the NewEPOC study. PMID 41314092 · Eur J Surg Oncol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. PMID 41308232 · Clin Lung Cancer · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD. PMID 41265834 · Contemp Clin Trials · 2026-Jan 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078]. PMID 41259940 · Eur J Cancer · 2026-Jan The record is a corrigendum to a safety analysis from a Phase III trial, not an original report of a primary/key secondary time-to-event efficacy endpoint. No efficacy data (e.g., OS, PFS, HR, Kaplan-Meier) are indicated in the provided metadata.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Utility of CA125 KELIM in predicting benefit from hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer: pooled analysis of KGOG3042 and KOV-HIPEC-01. PMID 41259849 · Int J Gynecol Cancer · 2026-Jan The study is a secondary pooled analysis focusing on a predictive biomarker for a surgical/chemotherapeutic procedure (HIPEC). While it involves a Phase III trial, the intervention of interest (HIPEC) is not a systemic drug therapy. The primary eligibility criterion of a drug-containing intervention is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis. PMID 41259845 · Int J Gynecol Cancer · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the prospective, randomised, phase III Evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial. PMID 41240797 · Eur J Surg Oncol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic scores for patients with multiple brain metastases treated with repeated stereotactic radiosurgery - a secondary analysis of the CYBER-SPACE randomized phase 2 trial. PMID 41232776 · Radiother Oncol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetics of Atogepant for the Prevention of Migraine. PMID 41222899 · Clin Pharmacokinet · 2026-Jan This is a population pharmacokinetic analysis for a migraine preventive drug (atogepant). The study is not oncology-focused, and it does not report a time-to-event efficacy endpoint. Therefore, it does not meet the core eligibility criteria for an oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pilot Study of Immediate Lymphatic Reconstruction (ILR) During Lymph Node Dissection for Node-Positive Melanoma: Feasibility, Safety, and Early Outcomes. PMID 41190591 · J Surg Oncol · 2026-Jan This is a prospective pilot study of a surgical technique (immediate lymphatic reconstruction) for melanoma. While it includes time-to-event endpoints and is an original result, it is not a randomized controlled trial, is not Phase III/IIIb or Phase II/III, and does not contain a drug-containing intervention. The deterministic review signal for phase3_evidence_unclear and drug_intervention=false are confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. PMID 41190384 · BJU Int · 2026-Jan The record is a secondary, post-hoc target trial emulation analysis of the ENZAMET trial data. While it uses data from a randomized trial and examines a time-to-event endpoint with drug interventions, it is not the original primary report of the Phase III ENZAMET trial itself, but a re-analysis within it.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Compound staphylococcal lysostaphin for oral mucositis prophylaxis in hematopoietic stem cell transplantation recipients: a non-inferiority randomized trial. PMID 41176574 · Br J Cancer · 2026-Jan The record does not meet key eligibility criteria: the trial phase is not confirmed as Phase III/IIIb or Phase II/III, the intervention is a non-drug supportive care mouthrinse, and the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial. PMID 41173355 · Radiother Oncol · 2026-Jan The study is a human oncology (breast cancer) Phase III randomized trial with original results, but it evaluates a non-drug intervention (radiation fractionation schemes) and reports only technical quality assurance data, not the primary or key secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the criteria for a drug-containing intervention with a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study. PMID 41145670 · Leukemia · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Low Versus High Ligation of Inferior Mesenteric Artery in Rectal and Sigmoid Cancers: A Systematic Review, Meta-analysis, and Trial Sequential Analysis of Randomized Controlled Trials. PMID 41139188 · Ann Surg Oncol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC). PMID 41138857 · Radiother Oncol · 2026-Jan The study is a randomized, placebo-controlled, multicenter trial in human oncology patients with a drug intervention (nimorazole) and reports time-to-event efficacy outcomes (including HR). However, the abstract and metadata do not explicitly state the trial phase (e.g., Phase III, Phase II/III). Without explicit phase information, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The results of randomized controlled trial comparing effectiveness of transanal endoscopic microsurgery versus endoscopic submucosal dissection. PMID 41136652 · Surg Endosc · 2026-Jan Excluded because it is not a drug intervention trial and the endpoints are not the required time-to-event efficacy endpoints for malignant neoplasms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Topical lidocaine or not for laser follicle ablation in pilonidal disease: A prospective, randomized, double-blinded trial. PMID 41135869 · J Pediatr Surg · 2026-Jan 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. PMID 41115464 · Ann Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial. PMID 41107178 · Eur Urol · 2026-Jan The record describes a randomized screening trial comparing diagnostic tests (PSA vs Stockholm3) for prostate cancer, not a therapeutic trial with a drug-containing intervention in a Phase III/IIIb or Phase II/III setting. Although it reports time-to-event outcomes (biochemical recurrence) and is an original result, the absence of a drug intervention and definitive Phase III therapeutic evidence makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). PMID 41087530 · Br J Cancer · 2026-Jan The study is a Phase III, prospective, non-randomized trial. The inclusion criteria require randomized trials.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tranexamic acid to prevent bleeding in patients with hematologic malignancies and hypoproliferative thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. PMID 41067389 · J Thromb Haemost · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
ASO Visual Abstract: Synergistic Effects of Psychological Resilience Training and Nutritional Support on Postoperative Recovery, Nutritional Reconstitution, Sleep Quality, and Long-term Survival in Gastric Cancer-A Randomized Controlled Trial. PMID 41057749 · Ann Surg Oncol · 2026-Jan The record lacks sufficient metadata to establish key criteria: no human subjects confirmation, no phase (Phase III/IIIb or II/III) confirmation, no drug-containing intervention (interventions are psychological/nutritional), no primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc., Kaplan-Meier, or HR) mentioned, and no confirmation of a primary result report. The title suggests a randomized trial in gastric cancer (oncology), but the core eligibility criteria are not met.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Bacterial decolonization with mupirocin ointment reduces severe radiation-induced oral mucositis in nasopharyngeal carcinoma: results of a randomized phase 3 trial]. PMID 41051489 · Strahlenther Onkol · 2026-Jan The record describes a randomized phase 3 trial in nasopharyngeal carcinoma (oncology) with a drug-containing intervention (mupirocin ointment), but the abstract provides no information on time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR data. The primary endpoint appears to be severe radiation-induced oral mucositis, which is a safety/toxicity endpoint, not a time-to-event efficacy endpoint. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort focused on time-to-event efficacy.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors According to Clinical Risk in Newly Diagnosed, Advanced Ovarian Cancer: A Meta-analysis of Phase III Clinical Trials. PMID 41042468 · Ann Surg Oncol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Does Messaging for Reducing Breast Cancer Overscreening in Older Women Have Differential Responses among Medical Minimizers and Maximizers? PMID 41020449 · Med Decis Making · 2026-Jan The study is a randomized controlled survey experiment evaluating a messaging intervention to reduce breast cancer overscreening. It is a non-drug-only intervention (messaging strategy), does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.), and is not a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention. It is therefore ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. PMID 40992967 · Ann Rheum Dis · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer. PMID 40956664 · J Urol · 2026-Jan The record describes a Phase II/III trial of a drug-containing regimen with primary time-to-event efficacy endpoints (DFS, PFS). However, the study appears to be a single-arm trial (open-label, no control group mentioned), and there is no explicit evidence of randomization. Therefore, it does not meet the requirement for a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[18F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics. PMID 40924149 · Eur J Nucl Med Mol Imaging · 2026-Jan The study is a Phase II/III imaging and dosimetry trial in Parkinson's disease (a non-oncology indication), not a malignancy. It is a human, original result report but lacks a drug intervention, is not randomized, and has no time-to-event efficacy endpoint. It does not meet any of the core eligibility criteria for the oncology Kaplan-Meier cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bioequivalence and Food Effect Assessment of Apalutamide Tablets Relative to Erleada in Healthy Chinese Male Participants. PMID 40862641 · Clin Pharmacol Drug Dev · 2026-Jan The record is a randomized, open-label, single-dose, crossover bioequivalence study of apalutamide in healthy volunteers. It does not meet the required criteria for a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The study focuses on pharmacokinetic parameters, not cancer treatment efficacy. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma. PMID 40803577 · J Hepatol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Reassessing survival outcomes: a closer look at the randomized trial on minimally invasive surgery for endometrial cancer. PMID 40783119 · Am J Obstet Gynecol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Randomized Trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms: DSETAMIS-2018 Study. PMID 40749854 · Gastroenterology · 2026-Jan The study is an oncology randomized trial with original results, but it does not meet key eligibility criteria: it is not explicitly a Phase III trial, it does not involve a drug-containing intervention (both are surgical/endoscopic procedures), and the primary endpoint (12-month recurrence) is not reported as a time-to-event analysis with Kaplan-Meier curves or hazard ratios.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation: An Early Remission Induction Study. PMID 40524500 · Arthritis Rheumatol · 2026-Jan The study is a Phase III trial of golimumab (a drug intervention) in human patients with axial spondyloarthritis, which is an inflammatory disease, not a malignant neoplasm (cancer). Therefore, it fails the core oncology eligibility criterion. Additionally, the trial is not randomized (it is a single-arm, open-label study) and the primary efficacy endpoint is not a time-to-event endpoint (it reports the proportion of patients achieving sustained clinical remission, not survival or progression outcomes with time-to-event analysis).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients. PMID 40419286 · Br J Haematol · 2026-Jan The publication is a comparative study of external versus internal control arms for a randomized trial, not the primary formal result report of the randomized Phase III trial. The trial phase is not explicitly stated in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized clinical trial to assess the effectiveness of thermal ablation versus loop electrosurgical excision procedure for cervical cancer risk reduction in women living with HIV in Mozambique. PMID 40399211 · Int J Gynecol Cancer · 2026-Jan The record describes a protocol for a randomized trial comparing two procedural interventions (thermal ablation vs. LEEP) for cervical precancer in women with HIV. It is not a drug intervention, does not specify Phase III, does not include time-to-event efficacy endpoints (OS, PFS, etc.), and is not a results report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
PERMA-based psychological intervention in glioma rehabilitation: An RCT examining affective distress, treatment adherence, and neuro-oncological outcomes. PMID 40340528 · Int J Psychiatry Med · 2026-Jan The study is a randomized trial in oncology with a time-to-event endpoint (Kaplan-Meier), but the intervention is a psychological intervention (PERMA-based), not a drug-containing intervention. Therefore, it does not meet the inclusion criteria requiring a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postoperative intravenous lidocaine infusion for pain management in pelvic bone tumor surgery patients: a randomized, double-blind, controlled trial. PMID 41764583 · J Anesth Analg Crit Care · 2026-Feb-28 The study is a randomized, double-blind, controlled trial in oncology patients (pelvic bone tumor surgery). However, it is excluded because the primary outcome is postoperative opioid consumption and other safety/efficacy metrics, not a time-to-event endpoint (e.g., OS, PFS, DFS). The intervention (lidocaine) is for perioperative pain management, not a systemic oncology drug intervention. The phase is not specified, but this does not affect eligibility as the key missing criterion is the endpoint type.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Feasibility and preliminary efficacy of an art-making program to manage fear of cancer recurrence (AM-I-FCR) in lung cancer patients: a randomized controlled pilot study. PMID 41761252 · BMC Med · 2026-Feb-27 The study is a randomized, human, oncology trial, but it is excluded because it is not Phase III/IIIb or Phase II/III (it is a pilot study), lacks a drug-containing intervention, and does not have a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. PMID 41760643 · Nat Commun · 2026-Feb-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy. PMID 41760424 · Eur Urol Focus · 2026-Feb-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy. PMID 41760422 · Eur Urol Focus · 2026-Feb-26 The study is an oncology-related (post-radical prostatectomy) randomized trial with original results, but it does not meet all inclusion criteria. The intervention is a cell therapy (ADRCs), not a drug. There is no time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.); the primary endpoint is a change in erectile function score. The trial phase is not explicitly stated, preventing confirmation of it being a definitive Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prophylactic LYMphatic Reconstruction (LYMbR) to prevent lymphedema after node dissection for cutaneous malignancies: a randomized controlled trial. PMID 41749241 · Trials · 2026-Feb-26 The record describes a Phase III randomized controlled trial protocol for a surgical intervention (prophylactic lymphatic reconstruction) to prevent lymphedema after node dissection for cutaneous malignancies. While it is oncology-related, human, randomized, and Phase III, it is a protocol without results and does not report a time-to-event efficacy endpoint. The intervention is non-drug, and no primary efficacy endpoint for time-to-event (e.g., overall survival, progression-free survival) is specified.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. PMID 41749205 · BMC Med · 2026-Feb-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial. PMID 41748622 · Nat Commun · 2026-Feb-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Frailty, comorbidity and survival comparisons between populations eligible for screening according to risk factor versus risk score criteria: results from the Yorkshire Lung Screening Trial. PMID 41593003 · Thorax · 2026-Feb-26 The record describes a randomized trial of lung cancer screening criteria, but the intervention is a screening program (non-drug), and the trial phase is not specified as Phase III/IIIb or Phase II/III. It does not meet all required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Digital Attention Bias in Cancer Survivors Intervention for Adolescent and Young Adult Cancer Survivors: Protocol for a Pilot Randomized Controlled Trial. PMID 41740148 · JMIR Res Protoc · 2026-Feb-25 The record is a protocol for a pilot randomized trial evaluating a digital psychosocial intervention (not a drug) in adolescent and young adult cancer survivors. It lacks results, is not Phase III, and has no time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term efficacy of ursodeoxycholic acid for the prevention of gallstone formation after gastrectomy in patients with gastric cancer: a randomized clinical trial. PMID 41738624 · Int J Surg · 2026-Feb-25 While the study is a randomized, double-blind, placebo-controlled trial in human gastric cancer patients with a time-to-event endpoint, it evaluates prevention of a post-surgical complication (gallstone formation) rather than an oncology efficacy endpoint like survival or tumor progression. Therefore, it does not meet the cohort's criteria for including trials with a primary or key secondary time-to-event efficacy endpoint for malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -